AbbVie Inc. (ABBV:NYSE) closed at $295.56 on November 13, 2026, up 0.38% on the day. The stock trades 2.4% below its 52-week high of $302.93 and 54.9% above its 52-week low of $190.75. Over the past year, it gained 26.8%. AbbVie Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 12, 2025, ABBV closed higher on 130 days (52%). Its best day was June 22, 2026 (+6.25%) and its worst was March 18, 2026 (-5.20%). It never moved 10% or more in a single session.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Furthe...
Find more stocks like ABBV with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.